Navidea Biopharma (NAVB) Tops Q1 EPS by 1c

Navidea Biopharma (NYSE: NAVB) reported Q1 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4.7 million versus the consensus estimate of $4.63 million.

The Company reiterates its 2016 total revenue estimate of $23 million to $25 million. Margins on Lymphoseek product sales are expected to continue to exceed 80% in the coming quarters. The Company also expects, following completion of the partnering activities for NAV4694, that cash operating expenses on a quarterly basis will continue to decrease to the point necessary for the Company to achieve its goals of cash flow breakeven from operations. This guidance excludes therapeutic-related research and development costs for the Manocept platform which are expected to be funded separately by Macrophage Therapeutics, Inc.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• ResMed (RMD) Tops Q3 EPS by 20c
• Eldorado Gold (EGO) Tops Q1 EPS by 10c